Skip to content
For laboratory research use only · Not for human consumption
Pioneer Labs

Fragments / Research guide

ARA-290.

A little deeper. A clearer picture.

A short peptide inspired by a surface of a much larger protein. ARA-290, also called cibinetide, was developed from structural features of erythropoietin (EPO).

For research use onlyView ARA-290 sizes
Published by Pioneer LabsUpdated Sources & editorial standards

01 / Molecular architecture

A closer look at the chain.

The reference peptide has 11 residues and a pyroglutamate at its N-terminus. Its design relates to the helix-B surface of EPO, not a miniature copy of the whole EPO protein.

Pioneer / Reference notesMolecular features
  • 11-residue reference
  • Pyroglutamate cap
  • EPO surface-inspired design
Structural features shown schematically, not a full sequence or three-dimensional model.

Reference information: [1][2]. Actual lot identity must be verified separately.

A surface-inspired design.

A protein surface can bring together features that are not captured by simply taking a long section of its sequence. ARA-290 is described as a helix-B-surface-inspired peptide. This is a design relationship to EPO, while the resulting reference is an independently defined eleven-residue molecule.

Reading the pyroglutamate cap.

The N-terminal pyroglutamate is a modified residue with a ring in its own structure. It is part of the reference’s chemical identity. That local ring does not mean the whole eleven-residue backbone is a cyclic peptide, and it should not disappear when the sequence is abbreviated for a diagram.

Structure and research references: [1]

02 / Read the evidence

Research & analytical context.

The reference describes an 11-residue peptide with a modified N-terminus. Its relationship to an EPO surface is a design reference; it does not give the fragment the same molecular identity as the complete protein.

Read the references: [1][2].

The distinction that matters

Keep the reference name, terminal modification and material identity together when reading papers. A proposed signaling mechanism is separate from evidence that a particular batch meets its specification.

03 / From reference to record

Know the lot, too.

A publication describes its own test material. Your lot’s certificate describes what was tested on that lot. Keep the compound name, batch number and reported methods together when reviewing a result.

Identity & composition

Check sequence or chemical form, terminal modifications, counterion and—where relevant—each blend component.

Analytical results

Read purity, content, sterility and endotoxin results as separate measurements. Only call a test passed when the actual report supports it.

Handling & storage notes

Lyophilized material: Store at −20°C; protect from light and moisture.

Follow the material-specific label and supporting storage documentation. These temperatures do not establish a shelf life.

How to store lyophilized peptides

04 / Reference questions

A few details, explained.

Are ARA-290 and cibinetide different compounds?

Cibinetide is a synonym for the ARA-290 reference. Synonyms help locate records, but matching names should still be followed by checking the sequence, terminal chemistry and chemical form used in each record.

Does an EPO-inspired design make it the EPO protein?

No. The design reference and the final molecule are different levels of description. ARA-290 is a short, specified peptide; calling it EPO-inspired does not give it the complete protein’s sequence or establish equivalent experimental behavior.

Read alongside the references: [1]

05 / Continue reading

Go to the source.